Review study on use of Galvus and Galvus/Met medicines
Phase 4
- Conditions
- Health Condition 1: null- Diagnosed with Type II diabetes mellitus
- Registration Number
- CTRI/2016/06/006991
- Lead Sponsor
- ovartis Healthcare Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 800
Inclusion Criteria
1.Adult (>= 18 years) T2DM patients of both genders, who have been prescribed vildagliptin or vildagliptin-metformin fixed-dose combination (Galvus or GalvusMet).
2.Written informed consent will be obtained from patients for use of their data in hospital database for the purpose of research
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the utilization of vildagliptin-metformin FDC in real-world scenario. <br/ ><br>Timepoint: Data would be collected from hospital medical records of patients with type 2 diabetes mellitus, who have been prescribed vildagliptin or its combination as per the discretion of the physician, during the study period (June 2016 - June 2017)
- Secondary Outcome Measures
Name Time Method To assess the utilization pattern of vildagliptin and its combinations in real-world scenario.Timepoint: Data would be collected from hospital medical records of patients with type 2 diabetes mellitus, who have been prescribed vildagliptin or its combination as per the discretion of the physician, during the study period (June 2016 - June 2017) <br/ ><br>